253 related articles for article (PubMed ID: 7947238)
1. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters.
van Prooijen HC; Visser JJ; van Oostendorp WR; de Gast GC; Verdonck LF
Br J Haematol; 1994 May; 87(1):144-7. PubMed ID: 7947238
[TBL] [Abstract][Full Text] [Related]
2. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
[TBL] [Abstract][Full Text] [Related]
3. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.
Bowden RA; Slichter SJ; Sayers M; Weisdorf D; Cays M; Schoch G; Banaji M; Haake R; Welk K; Fisher L; McCullough J; Miller W
Blood; 1995 Nov; 86(9):3598-603. PubMed ID: 7579469
[TBL] [Abstract][Full Text] [Related]
4. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors.
De Witte T; Schattenberg A; Van Dijk BA; Galama J; Olthuis H; Van der Meer JW; Kunst VA
Transplantation; 1990 Dec; 50(6):964-8. PubMed ID: 2175059
[TBL] [Abstract][Full Text] [Related]
5. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
Narvios AB; Lichtiger B
Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation.
Verdonck LF; de Graan-Hentzen YC; Dekker AW; Mudde GC; de Gast GC
Bone Marrow Transplant; 1987 Jun; 2(1):73-8. PubMed ID: 2844337
[TBL] [Abstract][Full Text] [Related]
7. [Experiences with transfusion of CMV tested blood preparations after bone marrow transplantation].
Luboldt W; Henneberg-Quester KB; Schaefer UW; Beelen DW; Quabeck K; Thraenhart O
Beitr Infusionsther; 1990; 26():190-3. PubMed ID: 1703827
[TBL] [Abstract][Full Text] [Related]
8. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant.
Bowden RA; Slichter SJ; Sayers MH; Mori M; Cays MJ; Meyers JD
Blood; 1991 Jul; 78(1):246-50. PubMed ID: 1648976
[TBL] [Abstract][Full Text] [Related]
9. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis.
Vamvakas EC
Transfus Med Rev; 2005 Jul; 19(3):181-99. PubMed ID: 16010649
[TBL] [Abstract][Full Text] [Related]
10. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening.
Miller WJ; McCullough J; Balfour HH; Haake RJ; Ramsay NK; Goldman A; Bowman R; Kersey J
Bone Marrow Transplant; 1991 Mar; 7(3):227-34. PubMed ID: 1647829
[TBL] [Abstract][Full Text] [Related]
11. Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a U.K. dual centre experience.
Hall S; Danby R; Osman H; Peniket A; Rocha V; Craddock C; Murphy M; Chaganti S
Transfus Med; 2015 Dec; 25(6):418-23. PubMed ID: 26114211
[TBL] [Abstract][Full Text] [Related]
12. Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland.
Voruz S; Gowland P; Eyer C; Widmer N; Abonnenc M; Prudent M; Masouridi-Levrat S; Duchosal MA; Niederhauser C
Blood Transfus; 2020 Nov; 18(6):446-453. PubMed ID: 32203012
[TBL] [Abstract][Full Text] [Related]
13. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group.
Gilbert GL; Hayes K; Hudson IL; James J
Lancet; 1989 Jun; 1(8649):1228-31. PubMed ID: 2566781
[TBL] [Abstract][Full Text] [Related]
14. The importance of pre bone marrow transplantation serology in determining subsequent cytomegalovirus infection. An analysis of risk factors.
Paulin T; Ringdén O; Lönnqvist B; Wahren B; Nilsson B
Scand J Infect Dis; 1986; 18(3):199-209. PubMed ID: 3016884
[TBL] [Abstract][Full Text] [Related]
15. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME).
Thiele T; Krüger W; Zimmermann K; Ittermann T; Wessel A; Steinmetz I; Dölken G; Greinacher A
Transfusion; 2011 Dec; 51(12):2620-6. PubMed ID: 21645009
[TBL] [Abstract][Full Text] [Related]
16. [Importance of screening for antibodies to cytomegalovirus in organ transplantation].
Milbradt H; Flik J; Stangel W; Heigel R
Beitr Infusionsther; 1990; 26():33-6. PubMed ID: 1703866
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products.
Rubie H; Attal M; Campardou AM; Gayet-Mengelle C; Payen C; Sanguignol F; Calot JP; Charlet JP; Robert A; Huguet F
Bone Marrow Transplant; 1993 Mar; 11(3):209-14. PubMed ID: 8385522
[TBL] [Abstract][Full Text] [Related]
18. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
[TBL] [Abstract][Full Text] [Related]
19. Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: a prospective study.
Preiksaitis JK; Desai S; Vaudry W; Roberts S; Akabutu J; Grundy P; Wilson B; Boshkov L; Hannon J; Joffres M
Transfusion; 1997 Sep; 37(9):941-6. PubMed ID: 9308642
[TBL] [Abstract][Full Text] [Related]
20. Prevention of transfusion-transmitted cytomegalovirus infection.
Pamphilon DH; Rider JR; Barbara JA; Williamson LM
Transfus Med; 1999 Jun; 9(2):115-23. PubMed ID: 10354380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
